Taking people in ItalyNo phase
EVOLUTION® Revision STEMMED CS Post Market Clinical Follow-up Study Protocol
Key facts
- Who runs it
- MicroPort Orthopedics Inc.
- Where
- Milan, ItalySee the site
- Trial code
- Status
- Recruiting
- People taking part
- 45 people, planned
- Started
- 31 Oct 2023
- Expected to end
- Dec 2036
- Type of study
- Observational
- Treatments tested
- EVOLUTION® Revision Tibial System and EVOLUTION® Stemmed CS Femur with the EVOLUTION® MP CS Tibial Insert
- Record updated
- 22 January 2024
Who can take part
- Age
- 21 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Has previously undergone or currently has been determined to undergo a revision knee arthroplasty that requires implantation of the components under study (EVOLUTION® Revision Tibial System and EVOLUTION® STEMMED CS Femur with the EVOLUTION® MP CS Tibial Insert)
- Decision to perform the study index surgery with the required study components is pre-determined regardless of the research
- Previously implanted subjects must be enrolled within 3 years (+ 6 months) of their study index surgery
- Willing to voluntarily sign the informed consent form
- Willing and able to comply with the protocol, able to read and complete the required forms, and willing and able to adhere to the requirements of the protocol through the 10-year postoperative follow-up visit
Who cannot take part
- Has or had inadequate neuromuscular status (e.g., prior paralysis, fusion, and/or inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable
- Has or had an overt infection at the time of implantation
- Has or had an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study
- Has a medical condition, as judged by the Investigator, that would interfere with the subject's ability to comply with the requirements of the protocol
- Skeletally immature (less than 21 years of age) at time of implantation
- Currently enrolled in another clinical investigation which could affect the endpoints of this protocol
- Has or had documented substance abuse issues
- Currently incarcerated or has impending incarceration
Where in Italy
- Gaetano Pini Orthopedic InstituteMilan, ItalyContact: Pietro Randelli, ProfTaking people
About the trial
What the trial wants to find out
MicroPort (MPO) is conducting this PMCF study to evaluate the safety and effectiveness of its EVOLUTION® Revision Tibial System and EVOLUTION® Revision STEMMED CS Femur with the EVOLUTION® MP CS Tibial Insert. This type of study is required by regulatory authorities for all devices that have been approved in Europe to evaluate the medium and long-term clinical evidence.
The group in the trial
- Revision Total Knee Arthroplasty
Single study group with either newly or previously implanted subjects with the EVOLUTION® Revision Tibia and EVOLUTION® Revision STEMMED CS Femur with the EVOLUTION® MP CS Insert.
Treatment: EVOLUTION® Revision Tibial System and EVOLUTION® Stemmed CS Femur with the EVOLUTION® MP CS Tibial Insert
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Post Market Clinical Follow-Up Study for EVOLUTION® Revision Tibial System and EVOLUTION® Stemmed CS Femur With the EVOLUTION® MP CS Tibial Insert
- Record updated
- 22 January 2024